Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ADH1B | P00325 | 2/20 | 0.40 |
| ▸ | ADH1C | P00326 | 2/20 | 0.40 |
| ▸ | ADH1A | P07327 | 2/20 | 0.40 |
| ▸ | ADH7 | P40394 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18112242 | 0.85 | CYP2C19 (0.40) | TSHRALDH1A1CYP2C19MEN1GLA | |
| SCHEMBL16775511 | 0.81 | CYP2C19 (0.60) | TSHRALDH1A1CYP2C19MEN1GLA | |
| SCHEMBL4525565 | 0.79 | TSHR (0.48) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL28088405 | 0.76 | CA12 (0.52) | TSHRALDH1A1CYP2C19MEN1KMT2A | |
| SCHEMBL4518806 | 0.76 | TSHR (0.50) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL432428 | 0.76 | TSHR (0.52) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL555017 | 0.75 | TSHR (0.44) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL21496029 | 0.75 | TSHR (0.44) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL2532 | 0.75 | — | — | |
| SCHEMBL27946380 | 0.75 | TSHR (0.79) | TSHRALDH1A1ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106010150-B | Thermosetting powder coating and coating product | 富士施乐株式会社 | 2019-10-11 | — | — | CN | disclosed |
| US-20180133749-A1 | METHOD FOR PRODUCING COATED ARTICLE | FUJI XEROX CO., LTD. (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20170087584-A1 | ELECTROSTATIC POWDER COATING METHOD AND POWDER COATING MATERIAL | FUJI XEROX CO., LTD. (JP) | 2017-03-30 | — | — | US | disclosed |
| CN-106010150-A | Thermosetting powder coating and coated article | 富士施乐株式会社 | 2016-10-12 | — | — | CN | disclosed |
| EP-2240492-B1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-07-07 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| EP-2240492-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. Organon (NL) | 2010-10-20 | — | — | EP | disclosed |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON | 2009-09-10 | — | — | US | disclosed |
| WO-2009087058-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON (NL) | 2009-07-16 | — | — | WO | disclosed |
| CN-101108825-A | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2008-01-23 | — | — | CN | disclosed |
| CN-1768041-A | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | TSHR 3446/4885ALDH1A1 600/4885ADH1B 134/4885 |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | TSHR 3446/4885ALDH1A1 600/4885ADH1B 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.